Source:http://linkedlifedata.com/resource/umls/id/C1721377
PDQ: An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). Nilotinib interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=435988&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=435988&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.n